Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-7050 is a cell-permeable small molecule that acts as a selective inhibitor of Tumor Necrosis Factor Receptor 1 (TNFR1) signaling. It functions by preventing the internalization of the TNFR1 complex, a critical step for the activation of downstream pro-inflammatory signaling cascades, including the NF-κB and MAPK pathways. Unlike traditional TNF-α inhibitors that neutralize the cytokine itself, R-7050 specifically targets the receptor's intracellular trafficking and signaling assembly. Preclinical studies have highlighted its potential in mitigating neuroinflammation, reducing edema, and preserving blood-brain barrier integrity in models of intracerebral hemorrhage and ischemic stroke. It is primarily utilized as a high-affinity pharmacological tool in biochemical research to dissect TNFR1-mediated biological processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on R-7050.